Via The Blue State Conservative
Back in November 2021, the White House paid drugmaker Pfizer nearly $5.3 billion ($5,290,000,000) for 10 million treatment courses of its experimental COVID-19 treatment. Paxlovid is an antiviral combination of nirmatrelvir and ritonavir.
Ritonavir was developed in 1989 and nirmatrelvir was developed in 2020. In other words, Paxlovid wasn’t developed from scratch to treat COVID-19; the compounds already existed.
